Bioequivalence and Bioavailability Forum 12:48 CET

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Narrow Therapeutic Index- valproic acid and derivatives [Regulatives / Guidelines]

posted by MaggieSantos - Portugal, 2017-04-26 18:20  - Posting: # 17271
Views: 1,666

Dear colleagues,

Concerning valproic acid and derivatives is not consentaneous that it should be considered as a narrow therapeutic índex for bioequivalence purposes. I know that for FDA it is a NTI. Do you have information for EMA, for individual European countries and for other countries around the World.

Depending on the submission country, the BE interval will differ.
Please, feel free to comment.

I need the more information I can get.

Kind Regards

MaggieSantos

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,883 posts in 4,027 threads, 1,271 registered users;
online 24 (0 registered, 24 guests [including 20 identified bots]).

Those who make no mistakes are making the biggest mistakes of all –
they are attempting nothing new.    Anthony de Mello

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed